Lipum: Change of CEO - Redeye realtid.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from realtid.se Daily Mail and Mail on Sunday newspapers.
Press release: Umeå, March 9, 2022. Lipum AB announce that the company has entered into an agreement with QPS Netherlands BV for the first-in-man phase I-study of the drug candidate SOL-116.. | March 9, 2022
Nasdaq Nordic: Nasdaq Stockholm Welcomes Lipum to the Nasdaq First North Growth Market
Stockholm, April 22, 2021 - Nasdaq (Nasdaq: NDAQ) announces that trading in
Lipum AB s shares (short name LIPUM) commences today on Nasdaq First North
Growth Market. The company belongs to the Health care sector. Lipum is the 39th
company to be admitted to trading on Nasdaq s Nordic markets in 2021.
Lipum is a biopharmaceutical company specialized on a novel way to treat
chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully
humanized antibody designed to give safer and more efficacious therapy by
blocking a previously overlooked target molecule of the immune system.
Lipum plans to list on Nasdaq First North Growth Market in spring of 2021 mynewsdesk.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mynewsdesk.com Daily Mail and Mail on Sunday newspapers.